A carregar...
Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers
Of the three RAS oncoproteins, only HRAS is delocalized and inactivated by farnesyltransferase inhibitors (FTI), an approach yet to be exploited clinically. In this study, we treat mice bearing Hras-driven poorly differentiated and anaplastic thyroid cancers (Tpo-Cre/Hras(G12V)/p53(flox/flox)) with...
Na minha lista:
| Publicado no: | Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6095730/ https://ncbi.nlm.nih.gov/pubmed/29760048 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-1925 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|